Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA-seq datasets of Ro, GSK-591 and combination treatment in Z-138 cells

ABSTRACT: RNA-seq datasets of Ro, GSK-591 and combination treatment in Z-138 cells

PROVIDER: PRJNA800374 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR17735674_1.fastq.gz	Fastqsanger.gz
	SRR17735674_2.fastq.gz	Fastqsanger.gz
	SRR17735675_1.fastq.gz	Fastqsanger.gz
	SRR17735675_2.fastq.gz	Fastqsanger.gz
	SRR17735676_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 24

Similar Datasets

RNA-seq datasets of Ro, GSK-591 and combination treatment in Z-138 cells

Project description:Dual targeting of PRMT5 and MSI2 inhibited synergisticly B-cells proliferation. Thus, next-generation sequencing was performed to evaluate the effect of the inhibitors of PRMT5 and MSI2, GSK-591 and Ro, respectively, in the global transcriptome of the mantle cell lymphoma cell line, Z-138.

2022-08-17 | GSE194360 | GEO

Ro, GSK-591 and combination treatment in Z-138 cells

Project description:Ro, GSK-591 and combination treatment in Z-138 cells

| PRJNA800369 | ENA

HyperTRIBE uncovers MSI2 RNA binding activity and the effect of Ro, GSK-591 and combination in Z-138 cells

Project description:Identifying MSI2 RNA-direct binding targets in B-cell lymphoma and evaluating how MSI2 binding activity can be affected by the inhibition of PRMT5 using GSK-591 and the MSI2 inhibitor, Ro and the combination of the two agents.

2022-08-17 | GSE194362 | GEO

HyperTRIBE uncovers MSI2 RNA binding activity and the effect of Ro, GSK-591 and combination in Z-138 cells

Project description:HyperTRIBE uncovers MSI2 RNA binding activity and the effect of Ro, GSK-591 and combination in Z-138 cells

| PRJNA800373 | ENA

Ro, GSK-591 and combination treatment in Z-138 cells

Project description:This SuperSeries is composed of the SubSeries listed below.

2022-08-16 | GSE194363 | GEO

Gene expression in astrocytes upon sustained GSK-3 inhibition by small molecule

Project description:In order to identify molecular targets that mediates the stimulation of astrocyte's migration upon sustained specific inhibition of GSK-3, we have employed whole genome microarray expression profiling. Murine cortical-striatal astrocytes grown in primary culture were treated in vitro for 48 h with either 1 micromolar Ro3303544, or control medium (final equivalent concentration of DMSO), or washed-out for 48h in control medium after an initial 48h treatment with 1 micromolar Ro3303544. The three different conditions: Ctrl, Ro and wash-out (each in duplicate) were compared.

2011-08-31 | E-GEOD-25770 | biostudies-arrayexpress

The DNMT1 inhibitor GSK-3484862 mediates global demethylation in murine embryonic stem cells

Project description:We generated WGBS datasets from mESCs treated with the novel drug GSK-3484862 attained from two different commercial sources or the conventional DNMT1 inhitibitor 5-azacytidine. To assess efficacy, datasets were generated from mESCs treated with GSK-3484862 at two concentrations and after treatment for 6 days and 14 days each. Additionally, for comparison purposes, we generated WGBS datasets from Dnmt1/3a/3b deficient mESCs which have very low levels of DNA methylation and WT mESCs treated with DMSO which retain high levels of DNA methylation.

2021-12-14 | GSE184116 | GEO

GSK-3A and GSK-3B knockdown in AML cell lines

Project description:Gene expression data from AML cell lines, MOLM-14, U937, THP-1 and HL-60, that were infected with a scrambled control hairpin (shControl), two shRNAs directed against GSK-3B (shGSK3B_1 and shGSK3B_2), or two shRNAs directed against GSK-3A (shGSK3A_5 and shGSK3A_6). Acute myeloid leukemia (AML) is the most common form of acute leukemia in adults. Long-term survival of patients with AML has changed little over the past decade, necessitating the identification and validation of new AML targets. Integration of genomic approaches with small-molecule and genetic-based high-throughput screening holds the promise of improved discovery of candidate targets for cancer therapy. Here, we identified a role for glycogen synthase kinase 3A (GSK-3A) in AML by performing two independent small-molecule library screens and an shRNA screen for perturbations that induced a differentiation expression signature in AML cells. GSK-3 is a serine-threonine kinase involved in diverse cellular processes including differentiation, signal transduction, cell cycle regulation, and proliferation. We demonstrated that specific loss of GSK-3A induced differentiation in AML by multiple measurements, including induction of gene expression signatures, morphological changes, and cell surface markers consistent with myeloid maturation. GSK-3AM-bM-^@M-^Sspecific suppression also led to impaired growth and proliferation in vitro, induction of apoptosis, loss of colony formation in methylcellulose, and anti-AML activity in vivo. Although the role of GSK-3B has been well studied in cancer development, these studies support a role for GSK-3A in AML. The AML cell lines, MOLM-14, U937, THP-1 and HL-60, were infected with a scrambled control hairpin (shControl), two shRNAs directed against GSK-3B (shGSK3B_1 and shGSK3B_2), and two shRNAs directed against GSK-3A (shGSK3A_5 and shGSK3A_6).

2012-02-27 | E-GEOD-35200 | biostudies-arrayexpress

landfill leachate RO

Project description:landfill leachate RO Raw sequence reads

| PRJNA887845 | ENA

Clostridium beijerinckii strain:NRRL B-591

Project description:Clostridium beijerinckii NRRL B-591

| PRJNA322809 | ENA